GSK6853 is a GSK5959 structural analog with improved aqueous solubility (140 μg/mL vs. 8 μg/mL for GSK5959 in pH 7.4 PBS), affinity toward BRPF1 bromodomain (pKd = 9.5 vs 8.0 for GSK5959), cellular efficacy (pIC50 = 7.7 vs 6.0 for GSK5959; against NanoLuc-BRPF1 bromodomain interaction with Histone H3.3-HaloTag in HEK293 cells), and selectivity, displaying little or no inhibitory potency against a panel of 48 channels/receptors/enzymes and >1600-fold reduced affinity toward other bromodomains tested (>90-fold in the case of GSK5959), including those of BRPF2 (BRD1) and BRPF3. GSK6853 displays good bioavailability when administered via intraperitoneal injection in mice in vivo (Cmax = 469 ng/mL, Tmax = 0.25 h, F = 85%; 3 mg/kg i.p.). The structural analog GSK9311 serves as a good inactive control (125- and 185-fold reduced potency in cell-free and cell-based assays, respectively). For characterization details of GSK6853, please visit the
GSK6853 probe summary on the Structural Genomics Consortium (SGC) website.
GSK9311 is the negative control for the active enantiomer, GSK6853. GSK9311 is available from Sigma. To learn more about and purchase GSK9311,
click here.
To learn about other SGC chemical probes for epigenetic targets, visit
sigma.com/sgc
